AbbVie has launched its Produodopa for Parkinson’s in the EU, becoming the first and only 24-hour levodopa-based subcutaneous infusion therapy for the disease.

AbbVie has finally claimed FDA approval for its advanced Parkinson's disease therapy Vyalev, 18 months after the US regulator turned it down with a request for more data.

Medicare covers medications, therapies, and other services for treating Parkinson’s disease and its symptoms, though beneficiaries should expect some out-of-pocket costs. Different parts of ...

From migraine to Parkinson’s and obesity, AbbVie is building dominant franchises across multiple high-growth areas. Read why ABBV stock is a Strong Buy.

Dr. Anurag Varshney, Vice-President and Chief Scientist of Patanjali Research Foundation, stated that this is the first time ...

"Well, one MRI later, and they discovered that her little spine-adjacent cyst was actually an ovarian cyst. The anatomically ...

As a technology broadcaster and journalist, largely for the BBC, I've spent the best part of two decades deeply immersed in ...

This week will see a heat wave with an amber health alert coming into force - Dr Jason Seewoodhary gives advice on how to ...

Convatec announced that it received FDA approval for the delivery of a Parkinson's disease therapy through its Neria Guard ...

A drug used for Parkinson's disease has been shown to be effective in reducing the symptoms of difficult to treat depression, ...